Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data AXIM BIOTECHNOLOGIES, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
Revenue
0
0.05
0.05
0.05
0.2
0.8
0
0.06
0.01
0.04
Cost of revenue
0
0.05
0.15
0.04
0.01
0
0
Gross profit
0
-0
-0.11
0
0.19
0
0
Research and development
0
0.57
0.24
1.35
2.06
0
0.43
0.28
0.15
0.13
Selling, general and administrative
0.51
9.48
3.41
5.67
4.08
2.24
General and administrative
3.41
1.8
3.16
3.11
4.51
5.67
Operating expenses
0.51
10
3.65
3.15
5.22
3.11
4.95
14
4.66
2.79
Operating income
-0.51
-10
-3.76
-3.15
-5.04
-3.11
-4.95
-14
-4.65
-2.75
Interest expense
0.03
0.04
0.28
0.32
0.46
0.22
0.23
0.25
0.26
0.14
Interest income
0
0
0
0
0
0
0
Other non-operating income
0.03
0.04
-2.05
-1.02
-1.72
0.14
1.34
2.05
1.59
5.31
Pre-tax income
-0.54
-10.1
-5.81
-4.17
-6.75
-2.97
-6.29
-16
-6.24
-8.06
Income tax
0
0
0
0
0
0
0
0
0
0
Income from continuing operations
-0.54
-2.97
-6.29
-16
0
0
Net income
-0.58
-10.1
-5.81
-4.17
-6.75
-6.45
-6.41
-16
-6.24
-8.06
EBITDA
-0.51
-10
-3.76
-3.15
-5.03
-3.11
-4.93
-11.9
-4.23
-2.32
EPS, basic
-0.02
-0.27
-0.17
-0.08
-0.12
-0.10
-0.06
0.12
-0.04
-0.04
EPS, diluted
-0.02
-0.27
-0.17
-0.08
-0.12
-0.10
-0.06
0.12
-0.04
-0.04
Shares, basic (weighted)
33
37.1
41.7
53.3
57.3
61.9
110
Shares, diluted (weighted)
33
37.1
41.7
53.3
57.3
61.9
110
Balance sheet
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
Cash and equivalents
0.66
0.13
0.71
2.06
1.81
0.51
0.46
0.45
0.05
0.16
Receivables
0
0.32
0
Inventory
0
0.2
0.04
0.01
0.01
0.49
0
0.02
Other current assets
0.07
0.78
0.04
0.04
0.26
0.02
0.01
0
Total current assets
0.74
1.18
1.37
2.11
2.02
1.64
0.71
0.64
0.1
0.16
Property, plant and equipment
0
0.02
0.01
0.01
0.01
0
0.1
0.12
0.09
0.13
Lease right-of-use assets
0
0.13
0.08
0.02
0.23
Goodwill
0
2.46
0
Intangible assets
0.06
0.06
0.05
0.05
3.99
Other non-current assets
7.8
Total assets
0.74
1.26
1.45
2.19
2.09
1.69
11.3
5.32
4.21
4.12
Accounts payable
0.4
0.44
0.22
0.75
1.07
0.91
1.32
2.78
Accrued liabilities
0
0
0
Deferred revenue
0.33
0.3
Short-term debt
0.01
0.01
0.41
0.01
0
0
0.02
0.09
Total current liabilities
1.32
2.55
3.02
7.71
3.32
3.4
1.5
2.58
3.39
5.98
Long-term debt
1.68
0.14
Lease liabilities
0
0.08
0.02
Total liabilities
1.32
2.96
3.82
8.48
8.17
8.45
9.75
7.66
9.04
11.8
Total debt
0.02
4.89
Paid-in capital
0.11
9.03
15.7
15.9
22.9
28.6
43.2
51
59.2
64.5
Retained earnings
-0.69
-10.8
-18.1
-22.2
-29
-35.4
-41.8
-57.9
-64.1
-72.2
Shareholders' equity
-0.58
-1.7
-2.37
-6.76
1.57
-2.34
-4.83
-7.66
Total equity
-0.58
-1.7
-2.37
-6.28
-6.08
-6.76
1.57
-2.34
-4.83
-7.66
Total liabilities and equity
0.74
1.26
1.45
2.19
2.09
1.69
11.3
5.32
4.21
4.12
Shares outstanding
33
39.6
52.5
54.6
59.6
64.9
125
138
192
246
Cash flow statement
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
Net income
-0.58
-10.1
-5.81
-4.17
-6.75
-6.45
-6.41
16
-6.24
-8.06
Depreciation and amortization
0
0
0
0
0
0
0.02
2.12
0.43
0.43
Stock-based compensation
0
5.98
1.45
0.06
0.91
1.84
2.31
1.14
1.11
0.2
Change in receivables
0
-0.32
-0.02
Change in inventory
0
-0.05
0.15
0.03
-0
-0.48
-0.02
0.02
Change in payables
0.15
0.25
0.19
0.22
-0.12
0.15
0.53
0.28
0.66
0.77
Cash from operations
-0.34
-1.54
-1.29
-3.08
-4.85
-5.04
-3.22
-2.49
-2.04
-1.03
Capital expenditures
0
0.02
0
-0.1
-0.04
-0.01
0
Sales and maturities of investments
0
0.38
0
0
Cash from investing
0
-0.02
0
0
0
0.35
0.01
-0.05
-0.01
0
Debt repaid
-0.09
0
Stock issued
0.02
0
0.36
0
Cash from financing
1
1.03
1.87
4.43
4.59
3.4
3.15
2.53
1.65
1.14
Net change in cash
0.66
-0.53
0.58
1.34
-0.25
-1.29
-0.05
-0
-0.41
0.11
Free cash flow
-0.34
-1.52
-1.29
-3.31
-2.53
-2.05
-1.03
Interest paid
0
0
0.01
0.11
0.46
0.06
0
0
0.18
0
Income taxes paid
0
0
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2024; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-2,497.0%
Operating income / revenue.
EBITDA margin
-2,033.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-4,464.0%
Pre-tax income / revenue.
Net margin
-4,464.0%
Net income / revenue.
Operating cash flow margin
-819.2%
Cash from operations / revenue.
Return on assets (ROA)
-111.0%
Net income / average total assets.
R&D / revenue
97.8%
Research and development expense / revenue.
SG&A / revenue
2,034.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
99.0%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
463.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
345.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 5y
-27.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-2.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-28.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
14.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.00x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Debt / assets
160.0%
Total debt / total assets.
Liabilities / assets
355.8%
Total liabilities / total assets.
Net debt
$6.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Market cap + total debt - cash - short-term investments.
P/S
13.0x
Market cap / revenue.
EV/Sales
77.4x
Enterprise value / revenue.
Earnings yield
-342.4%
Net income / market cap (the inverse of P/E).
What was AXIM BIOTECHNOLOGIES, INC.'s revenue in fiscal 2023?
AXIM BIOTECHNOLOGIES, INC. reported revenue of $39.5K for fiscal 2023, 345.3% higher than the year before.
Was AXIM BIOTECHNOLOGIES, INC. profitable in fiscal 2023?
No. It reported a net loss of $8.1M.
How much free cash flow did AXIM BIOTECHNOLOGIES, INC. generate in fiscal 2023?
Cash from operations of $1.0M minus capital expenditures of $0.0 left free cash flow of -$1.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.